1
Yun He, Tao Jiang, Kelli L Kuhen, David Archer Ellis, Baogen Wu, Tom Yao Hsiang Wu, Badry Bursulaya: Oxindoles with anti-HIV activity. IRM, Emily Tongro Wu, Genomics Institute of the Novartis Research Foundation, April 17, 2007: US07205328 (9 worldwide citation)

The present invention relates to inhibition of viruses, e.g., HIV using oxindoles and compounds related to oxindoles. The invention further relates to methods for identifying and using agents, including small molecule chemical compositions that inhibit HIV in a cell; as well as to methods of prophyl ...


2
Tom Yao Hsiang Wu, Yongkai Li, Alex Cortez, Yefen Zou, Pranab Mishra, Xiaoyue Zhang, David Skibinski, Manmohan Singh, Nicholas Valiante: Compounds and compositions as TLR activity modulators. IRM, Novartis, Daniel E Raymond, Genomics Institute of the Novartis Research Foundation, June 18, 2013: US08466167 (7 worldwide citation)

The invention provides a novel class of compounds, pharmaceutical compositions comprising such compounds and methods of using such compounds to treat or prevent diseases or disorders associated with Toll-Like Receptors, including TLR7 and TLR8. In one aspect, the compounds are useful as adjuvants fo ...


3
Tom Yao Hsiang Wu, Yongkai Li, Alex Cortez, Kathy Yue, Xiaoyue Zhang, Manmohan Singh, David Skibinski: Compounds and compositions as TLR activity modulators. IRM, The Genomics Institute of the Novartis Research Foundation, Daniel E Raymond, June 2, 2015: US09045470 (4 worldwide citation)

The invention provides a novel class of compounds, immunogenic compositions and pharmaceutical compositions comprising such compounds and methods of using such compounds to treat or prevent diseases or disorders associated with Toll-Like Receptors 7. In one aspect, the compounds are useful as adjuva ...


4
Manmohan Singh, David A G Skibinski, Tom Yao Hsiang Wu, Yongkai Li, Alex Cortez, Xiaoyue Zhang, Yefen Zou, Timothy Z Hoffman, Jianfeng Pan, Kathy Yue: Adsorption of immunopotentiators to insoluble metal salts. Novartis, Helen Lee, Virginia Campen, April 19, 2016: US09315530 (2 worldwide citation)

Immunopotentiators can be adsorbed to insoluble metal salts, such as aluminum salts, to modify their pharmacokinetics, pharmacodynamics, intramuscular retention time, and/or immunostimulatory effect. Immunopotentiators are modified to introduce a moiety, such as a phosphonate group, which can mediat ...


5
Manmohan Singh, David A G Skibinksi, Tom Yao Hsiang Wu, Yongkai Li, Alex Cortez, Xiaoyue Zhang, Yefen Zou, Timothy Z Hoffman, Jianfeng Pan, Kathy Yue: Adsorption of immunopotentiators to insoluble metal salts. GLAXOSMITHKLINE BIOLOGICALS, Joseph Schuller, October 16, 2018: US10098949

Immunopotentiators can be adsorbed to insoluble metal salts, such as aluminum salts, to modify their pharmacokinetics, pharmacodynamics, intramuscular retention time, and/or immunostimulatory effect. Immunopotentiators are modified to introduce a moiety, such as a phosphonate group, which can mediat ...


6
Helene Juteau, Michel Gallant, Daniel Dube, Patrick Roy, Renee Aspiotis, Rejean Fortin, Patrick Lacombe, Daniel McKay, Tom Yao Hsiang Wu: Renin inhibitors. Merck Sharp & Dohme, James L McGinnis, Catherine D Fitch, December 18, 2012: US08334308

The present invention relates to biphenyl-based renin inhibitor compounds having amino-terminal groups, and their use in treating cardiovascular events and renal insufficiency.


7
Tom Yao Hsiang Wu, Helene Juteau, Michel Gallant, Daniel Dube, Patrick Roy, Renee Aspiotis, Erich I Grimm, Sebastien Laliberte, Austin Chen: Case of renin inhibitors. Merck Canada, James L McGinnis, Catherine D Fitch, January 1, 2013: US08343968

The present invention relates to piperidine-based renin inhibitor compounds having carboxylate or carboxylic acid terminal groups, and their use in treating cardiovascular events and renal insufficiency.


8
Tom Yao Hsiang Wu, Yongkai Li, Alex Cortez, Yefen Zou, Pranab Mishra, Xiaoyue Zhang, Nicholas Valiante: Compounds and compositions as TLR activity modulators. Daniel E Raymond, Gemonics Institute of the Novartis Research Foundation, November 25, 2014: US08895577

The invention provides a novel class of compounds, pharmaceutical compositions comprising such compounds and methods of using such compounds to treat or prevent diseases or disorders associated with Toll-Like Receptors, including TLR7 and TLR8. In one aspect, the compounds are useful as adjuvants fo ...


9
Tom Yao Hsiang Wu, Yefen Zou, Timothy Z Hoffman, Jianfeng Pan: Compounds and compositions as TLR2 agonists. Novartis, The Genomics Institute of the Novartis Research Foundation, Daniel E Raymond, June 14, 2016: US09365506

The invention provides a novel class of compounds, immunogenic compositions and pharmaceutical compositions comprising such compounds and methods of using such compounds to treat or prevent diseases or disorders associated with Toll-Like Receptors 2. In one aspect, the compounds are useful as adjuva ...


10
Tom Yao Hsiang Wu, Yefen Zou, Timothy Z Hoffman, Jianfeng Pan: Compounds (cystein based lipopeptides) and compositions as TLR2 agonists used for treating infections, inflammations, respiratory diseases etc. Daniel E Raymond, Genomics Institute of the Novartis Research Foundation, August 19, 2014: US08808703

The invention provides a novel class of compounds viz. generally lipopeptides like Pam3CSK4, immunogenic compositions and pharmaceutical compositions comprising such compounds and methods of using such compounds to treat or prevent diseases or disorders associated with Toll-Like Receptors 2. In one ...